The use of tracheostomy

selleck kinase inhibitor in the SHP099 management of patients with severe tetanus will undoubtedly prevent death due to asphyxia from laryngeal muscle spasm (and acute airway obstruction), respiratory muscle spasm and aspiration [18]. The low rate of tracheostomy in our study may be responsible for high mortality rate among tetanus patients. There was no obvious explanation for the low rate of tracheostomy in this study. Complication rate in the present study is high compared to other studies [6, 11]. However, the presence of complication did not significantly affect the outcome of tetanus patients. Our complication pattern was fairly similar to what was reported by Feroz and Rahman in Bangladesh [8]. We could not find any obvious reason in literature to explain Selleckchem Momelotinib this similarity. Much attention must therefore be paid to prevent these complications through early diagnosis and management. The prognosis of patients with tetanus has been reported variably. Overall, mortality is approximately 10-50%, however in certain age groups e.g. neonates it is as high as 90-95% [19]. In this study, mortality rate was 43.1% which is comparable with the observation reported by Mohammed et al [20], whereas Mchembe & Mwafongo [4] in Tanzania and Zziwa [21] in Uganda have reported

higher mortality rate of 72.7% and 47% respectively. The high mortality rate could be due to the gross inadequacy of human and material resources to manage severe tetanus in the intensive care unit, typical of developing countries like Tanzania [4, 22]. Various factors have been known to affect the prognosis

[11]. The poor prognostic factors in this study included age ≥ 40 years, shorter incubation periods (< 7 days), low rate of tracheostomy, and severity of tetanus. Most Phospholipase D1 of the deaths in our series were attributed to sudden cardiac arrest, respiratory failure and infective pulmonary complications, an observation similar to other studies [8, 21]. In this study, only 29.3% of the patients who were discharged cured received tetanus toxiod before discharged a figure fairly consistent with that of other studies [21, 22]. This finding calls for a need to provide health education on primary immunization and scheduled booster immunization that have greatly found to reduce the incidence of tetanus. The overall mean duration of hospital stay in this study was 34.12 ± 38.44 days (1-120 days) which is high compared to other studies [4, 9, 12, 16, 17]. In one study, the overall mean duration of hospital stay was 83.0 days [8]. Prolonged duration of hospital stay has an impact on hospital resources as well as on increased cost of heath care, loss of productivity and reduced quality of life. The potential limitation of this study is the fact that information about some patients was incomplete in view of the retrospective nature of the study. This might have introduced some bias in our findings.